

Sarah Townsend

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5655583/publications.pdf>

Version: 2024-02-01

10
papers

1,051
citations

1306789

7
h-index

1473754

9
g-index

10
all docs

10
docs citations

10
times ranked

2052
citing authors

#	ARTICLE	IF	CITATIONS
1	Pathogenesis of non-alcoholic fatty liver disease. QJM - Monthly Journal of the Association of Physicians, 2010, 103, 71-83.	0.2	581
2	Safety and efficacy of liraglutide in patients with type 2 diabetes and elevated liver enzymes: individual patient data meta-analysis of the LEAD program. Alimentary Pharmacology and Therapeutics, 2013, 37, 234-242.	1.9	204
3	The lysyl oxidase like 2/3 enzymatic inhibitor, PXS153A, reduces crosslinks and ameliorates fibrosis. Journal of Cellular and Molecular Medicine, 2019, 23, 1759-1770.	1.6	76
4	Systematic review: the natural history of alpha-1 antitrypsin deficiency, and associated liver disease. Alimentary Pharmacology and Therapeutics, 2018, 47, 877-885.	1.9	67
5	Non-alcoholic fatty liver disease in 2016. British Medical Bulletin, 2016, 119, 143-156.	2.7	61
6	Review article: new treatments in non-alcoholic fatty liver disease. Alimentary Pharmacology and Therapeutics, 2017, 46, 494-507.	1.9	50
7	Presentation and prognosis of liver disease in alpha-1 antitrypsin deficiency. Expert Review of Gastroenterology and Hepatology, 2018, 12, 745-747.	1.4	10
8	Rescue from liver transplantation: TIPSS and thrombectomy successfully treat a case of acute Budd-Chiari syndrome complicated by portal vein thrombosis. BJR case Reports, 2017, 3, 20160059.	0.1	1
9	Editorial: liver transplantation in patients with non-alcoholic fatty liver disease and obesity. Alimentary Pharmacology and Therapeutics, 2017, 46, 459-460.	1.9	1
10	Editorial: optimising non-invasive screening for advanced liver fibrosis in NAFLD. Alimentary Pharmacology and Therapeutics, 2017, 46, 899-900.	1.9	0